JP5833745B2 - 粘膜炎の治療に使用するための化合物 - Google Patents

粘膜炎の治療に使用するための化合物 Download PDF

Info

Publication number
JP5833745B2
JP5833745B2 JP2014511450A JP2014511450A JP5833745B2 JP 5833745 B2 JP5833745 B2 JP 5833745B2 JP 2014511450 A JP2014511450 A JP 2014511450A JP 2014511450 A JP2014511450 A JP 2014511450A JP 5833745 B2 JP5833745 B2 JP 5833745B2
Authority
JP
Japan
Prior art keywords
independently
alkyl
group
halo
npl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014511450A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014516033A5 (enExample
JP2014516033A (ja
Inventor
スコット，リチャード・ダブリュー
コークザック，ボゼナ
Original Assignee
セルシューティクス・コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セルシューティクス・コーポレーション filed Critical セルシューティクス・コーポレーション
Publication of JP2014516033A publication Critical patent/JP2014516033A/ja
Publication of JP2014516033A5 publication Critical patent/JP2014516033A5/ja
Application granted granted Critical
Publication of JP5833745B2 publication Critical patent/JP5833745B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
JP2014511450A 2011-05-16 2012-05-15 粘膜炎の治療に使用するための化合物 Expired - Fee Related JP5833745B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161486455P 2011-05-16 2011-05-16
US61/486,455 2011-05-16
PCT/US2012/037895 WO2012158672A2 (en) 2011-05-16 2012-05-15 Compounds for use in treatment of mucositis

Publications (3)

Publication Number Publication Date
JP2014516033A JP2014516033A (ja) 2014-07-07
JP2014516033A5 JP2014516033A5 (enExample) 2015-07-02
JP5833745B2 true JP5833745B2 (ja) 2015-12-16

Family

ID=47175383

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014511450A Expired - Fee Related JP5833745B2 (ja) 2011-05-16 2012-05-15 粘膜炎の治療に使用するための化合物

Country Status (14)

Country Link
US (6) US8802683B2 (enExample)
EP (1) EP2709619B1 (enExample)
JP (1) JP5833745B2 (enExample)
KR (1) KR102012164B1 (enExample)
CN (1) CN103957710B (enExample)
AU (1) AU2012255935B2 (enExample)
CA (1) CA2836099C (enExample)
DK (1) DK2709619T3 (enExample)
IL (1) IL229381B (enExample)
MX (1) MX2013013330A (enExample)
RU (1) RU2606128C2 (enExample)
TW (1) TWI520951B (enExample)
WO (1) WO2012158672A2 (enExample)
ZA (1) ZA201308541B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090092574A1 (en) 2006-12-29 2009-04-09 Scott Richard W Ophthalmic And Otic Compositions Of Facially Amphiphilic Polymers And Oligomers And Uses Thereof
DK2709619T3 (en) * 2011-05-16 2018-01-15 Cellceutix Corp RELATIONSHIPS FOR USING THE TREATMENT OF MUCOSITIS
CA2894202A1 (en) * 2012-12-18 2014-06-26 The Secretary Of State For Health Antimicrobial compounds, their synthesis and applications thereof
EP2956437B1 (en) * 2013-02-15 2023-05-10 Technische Universität Berlin Albicidin derivatives for the treatment of bacterial infections
EP2970586B1 (en) * 2013-03-15 2022-12-07 Genzyme Corporation Amine functional polyamides
JP6047203B2 (ja) * 2015-02-20 2016-12-21 セルセウティックス コーポレイション 消化管の炎症性疾患の予防および／または治療のための宿主防御タンパク質（ｈｄｐ）模倣薬
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
JP7050165B2 (ja) 2018-02-26 2022-04-07 ギリアード サイエンシーズ， インコーポレイテッド Ｈｂｖ複製阻害剤としての置換ピロリジン化合物
US11771694B2 (en) 2020-06-05 2023-10-03 Innovation Pharmaceuticals Inc. Arylamide compounds for treatment and prevention of viral infections
KR20240053580A (ko) 2021-08-30 2024-04-24 유니켐 레버러토리스 리미티드 염증성 질환의 치료용 단백질 조성물
CN114890982A (zh) * 2022-05-16 2022-08-12 内蒙古大学 一种季铵盐修饰的二苯并噻吩亚砜衍生物的制备方法
CN117402075B (zh) * 2023-10-17 2026-01-09 厦门大学深圳研究院 一种具有特异性抗肿瘤活性的可见光响应的人工h+/ci-离子通道的制备

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3496179A (en) 1967-10-11 1970-02-17 Pfizer & Co C 2-amino-3,4-dihydroquinazolines
AU665381B2 (en) 1992-01-23 1996-01-04 Morinaga Milk Industry Company Limited Antibacterial agent and treatment of article therewith
US6025326A (en) * 1995-07-07 2000-02-15 Intrabiotics Pharmaceuticals, Inc. Compositions and methods for the prevention and treatment of oral mucositis
US5994306A (en) * 1995-11-22 1999-11-30 Intrabiotics Pharmaceuticals, Inc. Fine-tuned protegrins
JP3090125B2 (ja) 1997-08-26 2000-09-18 千寿製薬株式会社 ソフトコンタクトレンズ用の眼科用組成物、ソフトコンタクトレンズの濡れ増強方法およびテルペノイドの吸着抑制方法
ES2198139T3 (es) 1998-08-20 2004-01-16 The University Of North Carolina At Chapel Hill Compuestos de dibenzotiofeno y procedimientos de uso de los mismos.
US20040152664A1 (en) 1998-09-02 2004-08-05 Allergan, Inc. Prednisolone compositions
US6440964B1 (en) 1998-09-30 2002-08-27 Alcon Manufacturing, Ltd. Compositions and methods for treating ophthalmic and otic infections
US6482799B1 (en) 1999-05-25 2002-11-19 The Regents Of The University Of California Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial
JP2001261674A (ja) 2000-03-22 2001-09-26 Mitsui Chemicals Inc ベンゾチオフェン誘導体およびそれを有効成分として含有する核内レセプター作動薬
FR2813080B1 (fr) 2000-08-17 2002-11-29 Stago Diagnostica Peptides anti-heparine
AU2002239545B2 (en) 2000-11-08 2006-10-05 Fxs Ventures, Llc Improved ophthalmic and contact lens solutions with a peroxide source and a cationic polymeric preservative
CA2434693A1 (en) * 2001-01-18 2002-10-17 Genzyme Corporation Ionene polymers and their use as antimicrobial agents
AU2002326375B2 (en) 2001-03-08 2006-12-21 The Trustees Of The University Of Pennsylvania Facially amphiphilic polymers as anti-infective agents
US7629317B2 (en) 2001-03-29 2009-12-08 The University Of Chicago Control of growth and repair of gastro-intestinal tissues by gastrokines and inhibitors
AR034372A1 (es) 2001-06-08 2004-02-18 Novartis Ag Composiciones farmaceuticas
WO2003024391A2 (en) * 2001-08-16 2003-03-27 Mucosal Therapeutics, Inc. Treatment and prevention of mucositis in cancer patients
WO2003100701A1 (en) 2002-05-28 2003-12-04 The Trustees Of The University Of Pennsylvania Methods, systems, and computer program products for computational analysis and design of amphiphilic polymers
CA2489378A1 (en) 2002-06-13 2003-12-24 The Trustees Of The University Of Pennsylvania Methods, systems, and computer program products for simulating biomembranes using coarse grain models
AU2003291087A1 (en) * 2002-11-19 2004-06-15 Genzyme Corporation Ionene oligomers and polymers
US9241917B2 (en) * 2003-03-17 2016-01-26 The Trustees Of The University Of Pennsylvania Facially amphiphilic polymers and oligomers and uses thereof
WO2004082643A2 (fr) 2003-03-20 2004-09-30 Shiseido International France Composition cosmetique
US20040202687A1 (en) 2003-04-14 2004-10-14 Babu M.K. Manoj Ciprofloxacin formulations and methods of making and using the same
US20050059639A1 (en) 2003-09-11 2005-03-17 Wei Edward T. Ophthalmic compositions and method for treating eye discomfort and pain
US20050065091A1 (en) 2003-09-18 2005-03-24 Gholam Peyman Stabilized ocular solutions
WO2005072246A2 (en) 2004-01-23 2005-08-11 The Trustees Of The University Of Pennsylvania Facially amphiphilic polyaryl and polyarylalkynyl polymers and oligomers and uses thereof
CA2570248A1 (en) * 2004-06-15 2005-12-29 Polymedix, Inc. Polycationic compounds and uses thereof
EP2325218A1 (en) 2004-07-23 2011-05-25 The Trustees Of The University Of Pennsylvania Antimicrobial copolymers and uses thereof
KR20080004475A (ko) 2005-02-25 2008-01-09 유니버시티 오브 매사추세츠 표면적으로 양친매성인 중합체 및 올리고머, 그 조성물 및암치료방법으로서의 그 용도
ATE485819T1 (de) * 2005-03-24 2010-11-15 Rottapharm Spa Benzamidin derivative zur behandlung und vorbeugung von mucositis
AU2006244080C1 (en) * 2005-05-10 2012-02-02 The University Of Chicago Use of peptides derived from the growth factor AMP-18 for the treatment of mucositis
US7951829B2 (en) * 2006-05-03 2011-05-31 Janssen Pharmaceutica Nv Benzimidazole modulators of VR1
JP2008137978A (ja) 2006-12-05 2008-06-19 Canon Inc カルバゾール誘導体及びこれを用いた有機発光素子
US20090092574A1 (en) * 2006-12-29 2009-04-09 Scott Richard W Ophthalmic And Otic Compositions Of Facially Amphiphilic Polymers And Oligomers And Uses Thereof
WO2009061697A1 (en) 2007-11-09 2009-05-14 The Board Of Trustees Of The University Of Illinois Anticoagulant antagonist and hemophilia procoagulant
AU2009276744A1 (en) * 2008-07-28 2010-02-04 Polymedix, Inc. Anti-malarial compounds
TWI478915B (zh) * 2008-10-27 2015-04-01 Cellceutix Corp 宿主防禦之合成模擬物及其用途
CA2746421A1 (en) * 2008-12-10 2010-06-17 Polymedix, Inc. Antimicrobial molecules for treating multi-drug resistant and extensively drug resistant strains of mycobacterium
UA110323C2 (en) * 2009-06-04 2015-12-25 Promedior Inc Derivative of serum amyloid p and their receipt and application
JP2013516470A (ja) * 2010-01-07 2013-05-13 ポリメディックス・インコーポレーテッド 抗ヘパリン化合物
TW201208677A (en) * 2010-08-21 2012-03-01 Polymedix Inc Facially amphiphilic compounds, compositions, and uses thereof in treating cancer
DK2709619T3 (en) * 2011-05-16 2018-01-15 Cellceutix Corp RELATIONSHIPS FOR USING THE TREATMENT OF MUCOSITIS
AU2012352621A1 (en) * 2011-12-13 2014-07-24 Cellceutix Corporation Cyclic compounds and methods of making and using the same
HK1203763A1 (en) * 2012-01-18 2015-11-06 Cellceutix Corporation Compounds and methods for treating candidiasis and aspergillus infections
WO2014093231A2 (en) * 2012-12-10 2014-06-19 Cellceutix Corporation Hybrid compounds and methods of making and using the same
WO2014093225A2 (en) * 2012-12-10 2014-06-19 Cellceutix Corporation Polycyclic compounds and methods of making and using the same
RU2675847C2 (ru) * 2013-05-28 2018-12-25 Морфохем Акциенгезельшафт Фюр Комбинаторише Хеми Комбинированные терапевтические средства, содержащие оксазолидинон-хинолоны, предназначенные для лечения бактериальных инфекций
JP6047203B2 (ja) * 2015-02-20 2016-12-21 セルセウティックス コーポレイション 消化管の炎症性疾患の予防および／または治療のための宿主防御タンパク質（ｈｄｐ）模倣薬

Also Published As

Publication number Publication date
US20120295922A1 (en) 2012-11-22
EP2709619A2 (en) 2014-03-26
KR102012164B1 (ko) 2019-08-20
US9457027B2 (en) 2016-10-04
TW201247654A (en) 2012-12-01
EP2709619A4 (en) 2015-04-22
US20140364364A1 (en) 2014-12-11
CA2836099C (en) 2020-06-16
CN103957710A (zh) 2014-07-30
US10603294B2 (en) 2020-03-31
WO2012158672A3 (en) 2014-05-08
US20190282521A1 (en) 2019-09-19
MX2013013330A (es) 2014-07-09
CN103957710B (zh) 2016-04-20
US20180064664A1 (en) 2018-03-08
TWI520951B (zh) 2016-02-11
US9795575B2 (en) 2017-10-24
US10206894B2 (en) 2019-02-19
IL229381A0 (en) 2014-01-30
WO2012158672A2 (en) 2012-11-22
US9155738B2 (en) 2015-10-13
US20160213668A1 (en) 2016-07-28
RU2606128C2 (ru) 2017-01-10
NZ618249A (en) 2016-03-31
US20170224640A1 (en) 2017-08-10
US8802683B2 (en) 2014-08-12
IL229381B (en) 2018-04-30
ZA201308541B (en) 2015-04-29
DK2709619T3 (en) 2018-01-15
KR20140078582A (ko) 2014-06-25
EP2709619B1 (en) 2017-10-11
JP2014516033A (ja) 2014-07-07
CA2836099A1 (en) 2012-11-22
RU2013155678A (ru) 2015-06-27
AU2012255935B2 (en) 2016-06-23

Similar Documents

Publication Publication Date Title
US10603294B2 (en) Compounds for use in treatment of mucositis
AU2012255935A1 (en) Compounds for use in treatment of mucositis
US20070219239A1 (en) Nitrogen-containing heterocycle derivatives, pharmaceutical compositions, and methods of use thereof as antiviral agents
US20110178104A1 (en) Anti-Heparin Compounds
BG63938B1 (bg) Бензамидинови производни и използването им като лекарствени средства с ltb4-антагонистично действие
US4310517A (en) Tumor-resolving and histolytic medicaments and their use
AU2014318748A1 (en) Novel anthranilic amides and the use thereof
JP2008531585A (ja) 表面が両親媒性のポリマーおよびオリゴマー、それらの組成物そして癌治療方法におけるそれらの使用
EP0391971A1 (en) IMPROVED TOXICITY CURVES IN CHEMOTHERAPY.
JP2013530244A (ja) 免疫調節の方法
JP2003508381A (ja) 高脂血症の予防または治療用薬剤の製造のためのビススルホンアミドの使用
JP2005336172A (ja) 腎虚血再灌流障害治療又は予防薬
JP2010520236A (ja) リソフィリンアナログとその使用法
NZ618249B2 (en) Compounds for use in treatment of mucositis
EP1299350B1 (en) Substituted benzamides for immune enhancement and for the treatment of cancer, infection and manic-depressive illness
CN115969991A (zh) 一种麻醉药的结合物及其制备方法和应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150514

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150514

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20150514

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20150611

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150629

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150903

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150930

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20151029

R150 Certificate of patent or registration of utility model

Ref document number: 5833745

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees